AstraZeneca (NYSE:AZN) updated its FY18 earnings guidance on Thursday. The company provided EPS guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.41.
A number of equities analysts have issued reports on the company. Zacks Investment Research lowered AstraZeneca from a hold rating to a sell rating in a research report on Friday, June 29th. Morningstar reaffirmed a hold rating on shares of AstraZeneca in a research report on Tuesday, June 12th. BMO Capital Markets reaffirmed a buy rating and issued a $41.00 target price on shares of AstraZeneca in a research report on Friday, May 25th. Finally, ValuEngine lowered AstraZeneca from a buy rating to a hold rating in a research report on Friday, June 1st. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $38.28.
Shares of AstraZeneca traded down $0.09, reaching $38.06, during trading on Friday, according to Marketbeat. The company’s stock had a trading volume of 385,773 shares, compared to its average volume of 3,025,591. AstraZeneca has a twelve month low of $28.43 and a twelve month high of $38.73. The firm has a market cap of $94.83 billion, a price-to-earnings ratio of 8.91, a PEG ratio of 2.01 and a beta of 0.60. The company has a quick ratio of 0.54, a current ratio of 0.73 and a debt-to-equity ratio of 1.08.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Are analyst ratings accurate?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.